MDx/CDx Focus: Austin Breast Center Offers BrevaGen; Epigenomics Studies Colon Cancer MDx vs FIT | GenomeWeb

Austin Breast Center Offers BrevaGen Breast Cancer Risk Dx

The Breast Center of Austin this week announced that patients being treated at the facility will have access to BrevaGen, a test that assesses risk of developing non-familial or sporadic breast cancer.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.